Olema Pharmaceuticals, Inc.

Section 16(a) of the Exchange Act requires that our executive officers, directors and 10% stockholders file reports of ownership and changes of ownership with the SEC. Such directors, executive officers and 10% stockholders are required by SEC regulation to furnish us with copies of all Section 16(a) forms they file.

SEC regulations require us to identify in this proxy statement anyone who filed a required report late during the most recent year. Based solely on our review of forms we received and written representations of our executive officers, directors and 10% stockholders, we believe that during the year ended December 31, 2024, all Section 16(a) filing requirements were satisfied on a timely basis, other than with respect to two transactions initially reported on a Form 4 filed by Graham Walmsley on December 17, 2024 which contained errors that were corrected in an amended Form 4 filed on December 18, 2024.